KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Inventory (2017 - 2026)

Amneal Pharmaceuticals has reported Inventory over the past 9 years, most recently at $606.3 million for Q4 2025.

  • For Q4 2025, Inventory fell 1.0% year-over-year to $606.3 million; the TTM value through Dec 2025 reached $606.3 million, down 1.0%, while the annual FY2025 figure was $606.3 million, 1.0% down from the prior year.
  • Inventory for Q4 2025 was $606.3 million at Amneal Pharmaceuticals, down from $614.5 million in the prior quarter.
  • Over five years, Inventory peaked at $614.5 million in Q3 2025 and troughed at $489.4 million in Q4 2021.
  • A 5-year average of $558.7 million and a median of $560.6 million in 2023 define the central range for Inventory.
  • Biggest five-year swings in Inventory: grew 17.89% in 2021 and later decreased 1.0% in 2025.
  • Year by year, Inventory stood at $489.4 million in 2021, then increased by 8.45% to $530.7 million in 2022, then rose by 9.54% to $581.4 million in 2023, then increased by 5.34% to $612.5 million in 2024, then fell by 1.0% to $606.3 million in 2025.
  • Business Quant data shows Inventory for AMRX at $606.3 million in Q4 2025, $614.5 million in Q3 2025, and $609.0 million in Q2 2025.